Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M37,330Revenue $M2,105Net Margin (%)15.9Z-Score22.5
Enterprise Value $M37,030EPS $3.8Operating Margin %34.3F-Score4
P/E(ttm))102Cash Flow Per Share $-2.0Pre-tax Margin (%)32.1Higher ROA y-yN
Price/Book15.810-y EBITDA Growth Rate %0Quick Ratio5.1Cash flow > EarningsY
Price/Sales16.25-y EBITDA Growth Rate %0Current Ratio5.5Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %35.2ROA % (ttm)13.5Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)20.4Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M101ROI % (ttm)53.3Gross Margin Increase y-yN

Gurus Latest Trades with REGN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
REGNAndreas Halvorsen 2014-06-30 Add2.39%$277.29 - $313.74
($296.6)
$ 366.1323%Add 181.75%2,963,456
REGNVanguard Health Care Fund 2014-06-30 Add0.79%$277.29 - $313.74
($296.6)
$ 366.1323%Add 60.34%2,795,500
REGNFrank Sands 2014-06-30 Add0.64%$277.29 - $313.74
($296.6)
$ 366.1323%Add 22.32%4,907,362
REGNRay Dalio 2014-06-30 Buy 0.04%$277.29 - $313.74
($296.6)
$ 366.1323%New holding, 18400 sh.18,400
REGNJoel Greenblatt 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 366.1323%New holding, 881 sh.881
REGNMario Gabelli 2014-06-30 Buy $277.29 - $313.74
($296.6)
$ 366.1323%New holding, 2295 sh.2,295
REGNAndreas Halvorsen 2014-03-31 Buy 1.3%$267.62 - $347.62
($307.2)
$ 366.1319%New holding, 1051800 sh.1,051,800
REGNVanguard Health Care Fund 2014-03-31 Add0.29%$267.62 - $347.62
($306.26)
$ 366.1320%Add 23.47%1,743,468
REGNFrank Sands 2014-03-31 Add0.22%$267.62 - $347.62
($307.2)
$ 366.1319%Add 7.48%4,012,062
REGNRon Baron 2014-03-31 Buy 0.01%$267.62 - $347.62
($307.2)
$ 366.1319%New holding, 6084 sh.6,084
REGNJoel Greenblatt 2013-12-31 Sold Out -0.03%$261.88 - $313.67
($287.35)
$ 366.1327%Sold Out0
REGNFrank Sands 2013-09-30 Add0.56%$227.65 - $309.174
($262.76)
$ 366.1339%Add 20.34%3,777,357
REGNJoel Greenblatt 2013-09-30 Buy 0.03%$227.65 - $309.174
($262.76)
$ 366.1339%New holding, 3285 sh.3,285
REGNRay Dalio 2013-09-30 Sold Out -0.01%$227.65 - $309.174
($262.76)
$ 366.1339%Sold Out0
REGNFrank Sands 2013-06-30 Add1.07%$178.51 - $282.8
($232.86)
$ 366.1357%Add 81.03%3,138,793
REGNRay Dalio 2013-06-30 Buy 0.01%$178.51 - $282.8
($232.86)
$ 366.1357%New holding, 4100 sh.4,100
REGNVanguard Health Care Fund 2013-03-31 Add0.62%$158.42 - $183.77
($171.66)
$ 366.13113%Add 170.41%1,412,100
REGNFrank Sands 2013-03-31 Reduce-1.02%$158.42 - $183.77
($171.66)
$ 366.13113%Reduce -46.22%1,733,896
REGNFrank Sands 2012-09-30 Reduce-1.2%$112.77 - $152.66
($135.2)
$ 366.13171%Reduce -37.57%3,834,373
REGNVanguard Health Care Fund 2012-09-30 Reduce-0.09%$112.77 - $152.66
($135.2)
$ 366.13171%Reduce -24.56%522,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

REGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
REGN Mario Gabelli 2014-06-302,29500New Buy
REGN Ray Dalio 2014-06-3018,4000.020.04New Buy
REGN Joel Greenblatt 2014-06-3088100New Buy
REGN Andreas Halvorsen 2014-06-302,963,4562.933.7+181.75%
REGN Vanguard Health Care Fund 2014-06-302,795,5002.772.1+60.34%
REGN Frank Sands 2014-06-304,907,3624.863.5+22.32%
REGN Ron Baron 2014-06-307,1090.010.01+16.85%
Premium Most recent portfolio changes are included for Premium Members only!


REGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2014-10-15Buy158,368$328.1612.64view
Sanofi10% Owner 2014-09-16Buy31,717$349.265.84view
Sanofi10% Owner 2014-09-15Buy140,632$345.157.1view
VAGELOS P ROYChairman of the Board 2014-09-10Sell10,328$350.075.59view
GOLDSTEIN JOSEPH LDirector 2014-08-27Sell2,000$350.315.52view
Tessier-Lavigne MarcDirector 2014-08-27Sell3,000$352.24.95view
Aberman Michael SVP Strategy and Investor Relat 2014-08-19Sell3,611$3505.61view
McCorkle Douglas SVP Controller and Asst Treasur 2014-08-18Sell5,875$3534.71view
BROWN MICHAEL SDirector 2014-08-15Sell3,000$349.25.85view
GOLDSTEIN JOSEPH LDirector 2014-08-14Sell2,000$347.656.33view

Press Releases about REGN :

    Quarterly/Annual Reports about REGN:

    News about REGN:

    Articles On GuruFocus.com
    S&P 500 Finishes Above 2,000 Aug 27 2014 
    How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
    Weekly Insider Sells Highlight: MSFT, REGN, ATVI, MAA Feb 17 2014 
    Insiders Are Buying Ophthotech Oct 08 2013 
    Weekly Top Insider Sells: REGN May 27 2013 
    comment on REGN Mar 06 2013 
    Edward Owens’ Vanguard Health Care Fund Does More Shedding than Adding in Third Quarter Nov 01 2012 
    52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 
    Regeneron Pharmaceuticals: Continuous loss making company delivers 2-year 600% gain in share price Sep 08 2012 
    52-Week High Companies: BAM, REGN, TRV, WFC Aug 20 2012 


    More From Other Websites
    Market Thorns, Roses, and All Time Highs... Oct 17 2014
    [$$] Amgen Files Patent Infringement Suit Oct 17 2014
    Two Tribes Go to War: Amgen Sues Regeneron for Patent Infringement Oct 17 2014
    Cramer: Regeneron's Head-to-Head Results 'Very Positive' Oct 17 2014
    Regeneron Eye Drug Beats Rivals While Amgen Sues Oct 17 2014
    Stocks Power Higher At Open; Regeneron Vaults On Eylea Trial Oct 17 2014
    [video] Positive for Regeneron: Cramer Oct 17 2014
    Regeneron's Eylea works better vs Avastin and Lucentis in study Oct 17 2014
    EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both... Oct 17 2014
    7:00 am Regeneron Pharms: EYLEA injection demonstrates significantly greater gains in visual acuity... Oct 17 2014
    EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both... Oct 17 2014
    'Mad Money' Lightning Round: Stay the Course With Facebook Oct 17 2014
    Lightning Round: Facebook, Regeneron & More Oct 16 2014
    Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 Oct 16 2014
    Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive... Oct 16 2014
    Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive... Oct 16 2014
    Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments Oct 16 2014
    Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments Oct 16 2014
    LinkedIn, YY Among 5 Stocks With Top Fundamentals Oct 16 2014
    Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and... Oct 15 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK